Retraction of Lancet, NEJM studies does not signal doubts about the utility of RWE for evaluating drug efficacy and safety; instead, it highlights importance of transparency, validation and audit trails for real-world datasets, and lack of familiarity with RWE methods among medical journal peer reviewers, experts say.
The prominent retraction of two observational studies on COVID-19 is unlikely to permanently taint interest in leveraging real-word evidence about drug efficacy and safety.
The withdrawal of the studies in the Lancet and New England Journal of Medicine, both led by Brigham and Women’s...